Skip to content

Clinical Study of QSOX1 as a Biomarker for Colon Cancer

Clinical Application of Sulfhydryl Oxidase QSOX1 as a New Biomarker of Colon Cancer

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05827471
Enrollment
400
Registered
2023-04-25
Start date
2023-07-01
Completion date
2026-12-31
Last updated
2023-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Brief summary

The goal of this observational study is to determine whether the secreted protein QSOX1 can be used as a molecular marker for early rapid diagnosis and accurate treatment of colon cancer.

Detailed description

The project mainly selects the tumor group represented by colon cancer and the corresponding healthy people as the control group, with about 100 cases in each of the two groups. Mainly collect blood and tumor tissue samples of patients, detect the expression of QSOX1 in the above samples, and explore the role in the diagnosis and prognosis evaluation of colon cancer.

Interventions

DIAGNOSTIC_TESTDiagnosis of colon cancer

Clinical diagnosis results

Sponsors

Qianfoshan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Colon cancer was confirmed by colonoscopic pathology. * No local or systemic treatment was performed before operation. * Complete clinical data.

Exclusion criteria

* Combined with benign diseases of colon, such as ulcerative colitis, colon adenoma and colon polyp. * Other tumors other than colon cancer.

Design outcomes

Primary

MeasureTime frameDescription
Detection of RNA for early rapid diagnosis of colon cancer.6 monthsRT-PCR was used to detect the RNA levels of QSOX1 in the tumor and control groups.
Detection of protein for early rapid diagnosis of colon cancer.6 monthsWestern blotting was used to detect the protein levels of QSOX1 in the tumor and control groups.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026